HMGB1-mediated restriction of EPO signaling contributes to anemia of inflammation

• Published in: Blood Vol. 139; no. 21; pp. 3181 - 3193
• Main Authors: Dulmovits, Brian M., Tang, Yuefeng, Papoin, Julien, He, Mingzhu, Li, Jianhua, Yang, Huan, Addorisio, Meghan E., Kennedy, Lauren, Khan, Mushran, Brindley, Elena, Ashley, Ryan J., Ackert-Bicknell, Cheryl, Hale, John, Kurita, Ryo, Nakamura, Yukio, Diamond, Betty, Barnes, Betsy J., Hermine, Olivier, Gallagher, Patrick G., Steiner, Laurie A., Lipton, Jeffrey M., Taylor, Naomi, Mohandas, Narla, Andersson, Ulf, Al-Abed, Yousef, Tracey, Kevin J., Blanc, Lionel
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 26.05.2022; American Society of Hematology
• Subjects: Anemia; Anemia - genetics; Animals; Erythropoiesis; Erythropoiesis - genetics; Erythropoietin; Erythropoietin - metabolism; HMGB1 Protein; Inflammation; Mice; Receptors, Erythropoietin; Receptors, Erythropoietin - metabolism; Red Cells, Iron, and Erythropoiesis; Sepsis; Sepsis - complications

Anemia of inflammation, also known as anemia of chronic disease, is refractory to erythropoietin (EPO) treatment, but the mechanisms underlying the EPO refractory state are unclear. Here, we demonstrate that high mobility group box-1 protein (HMGB1), a damage-associated molecular pattern molecule re...